Government Hospital in Tiruchi Launches Monthly Nutritional Support Scheme for Cancer Patients
Mahatma Gandhi Memorial Government Hospital in Tiruchi has launched a monthly nutritional support program providing protein-rich food packs to 20 cancer patients undergoing chemotherapy. The initiative, developed in partnership with the Indian Medical Association's Tiruchi chapter and the Tiruchi Oncology Society, addresses a critical gap where patients can access free chemotherapy but struggle to afford adequate nutrition. The program prioritizes economically disadvantaged patients and aims to ensure they receive the 60-80 grams of daily protein needed for effective cancer treatment.
A new nutritional support scheme was launched this week at Mahatma Gandhi Memorial Government Hospital (MGMGH) in Tiruchi to provide monthly nutrition packs to 20 cancer patients undergoing chemotherapy. Each pack, valued at ₹1,200, contains protein-rich items such as pulses, lentils, and sunflower oil. The program was initiated by the hospital in collaboration with the Indian Medical Association's Tiruchi chapter and the Tiruchi Oncology Society, with IMA members sponsoring the hampers for the year. Medical officials noted that cancer patients often experience sudden weight loss and loss of appetite, making adequate protein intake—60-80 grams daily—essential for treatment efficacy. Priority will be given to patients from economically weaker sections. The hospital's cancer outpatient department, which opened in January 2026, currently serves approximately 300 patients monthly, including referrals from surrounding districts.
What different sources said
- The HinduCenter
Initiative at MGMGH to provide nutritional packs to 20 cancer patients at a monthly scheme
Related
Multi-Cancer Blood Test Galleri Fails Primary Trial Endpoint
A major clinical trial of Galleri, a blood test designed to detect multiple cancers early, failed to meet its primary goal of reducing late-stage cancer diagnoses when results were announced in February. Multi-cancer early detection (MCED) tests aim to improve survival rates by identifying disease at earlier, more treatable stages. The failure raises questions about the effectiveness of this promising diagnostic approach despite initial scientific enthusiasm.
Study Uses CPAP Data to Measure Social Jet Lag in Sleep Apnea Patients
Researchers analyzed CPAP adherence records from nearly 3,000 obstructive sleep apnea patients to measure social jet lag—the circadian misalignment between work and free days. About 16-21% of patients showed moderate to severe social jet lag, with prevalence highest in younger and middle-aged adults and declining after age 65. The findings suggest CPAP devices could routinely screen for circadian misalignment, potentially identifying patients who need additional behavioral or activity-based interventions.
FDA Updates Alli Label to Warn of Rare but Potentially Fatal Kidney Problems
The FDA has approved updated labeling for Alli, an over-the-counter weight loss pill, to warn of rare risks including acute kidney injury, kidney stones, and oxalate nephropathy. The agency now instructs people with kidney disease history to consult a doctor before use and directs all users to stop taking the drug if they experience symptoms like back pain, blood in urine, or leg swelling. This warning is significant because Alli is the only OTC weight loss medication available in the U.S., and approximately 40 million people have used orlistat (Alli's generic form) since its approval in 1999.